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Abstract
Background and Objective
To describe the impact of coronavirus disease 2019 (COVID-19) on people with neuromyelitis
optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody
disease (MOGAD).
Methods
The COVID-19 Infections in Multiple Sclerosis (MS) and Related Diseases (COViMS)
Registry collected data on North American patients with MS and related diseases with
laboratory-positive or highly suspected SARS-CoV-2 infection. Deidentiﬁed data were entered
into a web-based registry by health care providers. Data were analyzed using t-tests, Pearson χ 2
tests, or Fisher exact tests for categorical variables. Univariate logistic regression models examined eﬀects of risk factors and COVID-19 clinical severity.
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Results
As of June 7, 2021, 77 patients with NMOSD and 20 patients with MOGAD were reported in the
COViMS Registry. Most patients with NMOSD were laboratory positive for SARS-CoV-2 and
taking rituximab at the time of COVID-19 diagnosis. Most patients with NMOSD were not
hospitalized (64.9% [95% CI: 53.2%–75.5%]), whereas 15.6% (95% CI: 8.3%–25.6%) were hospitalized only, 9.1% (95% CI: 3.7%–17.8%) were admitted to the ICU and/or ventilated, and 10.4%
(95% CI: 4.6%–19.5%) died. In patients with NMOSD, having a comorbidity was the sole factor
identiﬁed for poorer COVID-19 outcome (OR = 6.0, 95% CI: 1.79–19.98). Most patients with
MOGAD were laboratory positive for SARS-CoV-2, and almost half were taking rituximab. Among
patients with MOGAD, 75.0% were not hospitalized, and no deaths were recorded; no factors were
diﬀerent between those not hospitalized and those hospitalized, admitted to the ICU, or ventilated.
Discussion
Among the reported patients with NMOSD, a high mortality rate was observed, and the
presence of comorbid conditions was associated with worse COVID-19 outcome. There were
no deaths reported in the patients with MOGAD, although these observations are limited due
to small sample size.
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Glossary
COVID-19 = coronavirus disease 2019; COViMS = COVID-19 Infections in MS and Related Diseases; DMT = diseasemodifying therapy; ICU = intensive care unit; MOGAD = myelin oligodendrocyte glycoprotein antibody disease; MS =
multiple sclerosis; NMOSD = neuromyelitis optica spectrum disorders; SARS-CoV-2 = severe acute respiratory syndrome
coronavirus 2.

The coronavirus disease 2019 (COVID-19) pandemic caused
by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) raised concerns about the risks of COVID-19 in those
with neuroimmunologic disorders that aﬀect the CNS. Risk
factors associated with worse COVID-19 outcomes in multiple sclerosis (MS) include increased hospitalizations with
B cell–depleting therapies, recent treatment with glucocorticoid use, and Black or African American race.1,2 However,
little data have been reported on how COVID-19 aﬀects
people with neuromyelitis optica spectrum disorders
(NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD).
NMOSD and MOGAD are distinct disorders that have a
spectrum of presentations and unique autoantibodies that differentiate them from MS and other diseases. Disability levels
vary in NMOSD and MOGAD, with the former often associated with a greater disability. However, outcomes of COVID19 in people with NMOSD or MOGAD are largely unknown,
especially in those with preexisting medical comorbidities and/
or taking speciﬁc disease-modifying therapies (DMTs).
The rarity of coexisting SARS-CoV-2 and these autoantibodyassociated disorders make them well suited to a registry-based
study. The COVID-19 Infections in MS and Related Diseases
(COViMS) Registry was designed to collect information on
COVID-19 in people with MS, NMOSD, and MOGAD from
North American health care professionals. Here, we aimed to
describe the clinical characteristics, risk factors for severe
course of COVID-19, and overall COVID-19 outcomes in
patients with NMOSD and MOGAD.

Methods
Study Design
The COViMS Registry collected data on patients in North
America who had a laboratory positive or highly suspected
infection with SARS-CoV-2 with MS and other related diseases, including NMOSD and MOGAD.1 Highly suspected
patients for SARS-CoV-2 infection were identiﬁed by a health
care professional based on typical COVID-19 symptoms and
signs (e.g., anosmia, ageusia, shortness of breath, and pneumonia) with no better explanation for their symptoms/signs.
Health care professionals were asked to report patients after a
minimum of 7 days from initial infectious symptom onset and
when suﬃcient time had passed to observe the COVID-19
disease course through resolution of acute illness or death.1
The COViMS Registry is jointly supported by the Consortium
2

of MS Centers, the National MS Society USA, and the MS
Society of Canada.1
Data collection was de-identiﬁed, cross-sectional, and entered
into a secure, online database on the COViMS Registry website
(COViMS.org) using the REDCap system (project-redcap.
org).1 The Registry was determined to be not human subject
research by the WUSTL Institutional Review Board. Data use
agreements govern the use of some data that were contributed,
and thus, access to individual level data is not permitted by
outside researchers.1 Data collection began April 1, 2020, and is
ongoing.1 The study herein used data collected from April 1,
2020, through June 7, 2021.
COVID-19 Clinical Outcome
Health care professionals indicated whether the patient was
hospitalized, admitted to the intensive care unit (ICU), required ventilator support, and/or died during their COVID19 clinical course, with response options of “yes,” “no,” or
“unknown” to each.1 Unknown responses were considered as
not having the outcome.1 These separate outcomes were used
to characterize COVID-19 severity, with the following levels:
not hospitalized, hospitalization alone, ICU admission and/or
ventilation and death where if more than 1 event was indicated, the patient was assigned to the highest level of event
that occurred.1
Demographic and Clinical Characteristics
Demographic factors collected were sex (male, female, and
nonbinary), age, race (White; Black or African American
[Black]; Asian; American Indian, Alaska Native, or Indigenous
Canadian; Native Hawaiian or Other Paciﬁc Islander; other; or
unknown), and ethnicity (Hispanic/Latino, not Hispanic/
Latino, other, or unknown).1
Clinical characteristics collected include disease type (if
NMOSD, NMO-IgG or aquaporin-4 antibody status noted),
disease duration, and ambulation milestones (fully ambulatory,
walks with assistance, and nonambulatory).1 Comorbid conditions were indicated by selecting all applicable including
cancer, cardiovascular disease, cerebrovascular disease, chronic
kidney disease, chronic liver disease, chronic lung disease,
chronic neurologic and/or neuromuscular disease, diabetes,
hypertension, immunodeﬁciency disease, and morbid obesity.1
Comorbid conditions were also summed to categorize the
count as 0 (reference), 1, 2, and ≥3 comorbidities.1 Cigarette
use history was captured as never, past, current, or unknown.1
Glucocorticoid treatment during the prior 2 months was
ascertained.1 Current DMT at the time of SARS-CoV-2
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infection was reported by the provider as one of the following:
alemtuzumab, azathioprine, cladribine, daclizumab, dimethyl
fumarate, diroximel fumarate, eculizumab, ﬁngolimod, glatiramer acetate, hematopoietic stem cell transplant, interferonbeta, intravenous immunoglobulin, methotrexate, mitoxantrone, mycophenolate, natalizumab, ocrelizumab, ofatumumab,
ozanimod, rituximab, satralizumab, tocilizumab, siponimod,
teriﬂunomide, other, none, and unknown.1
Statistical Analysis
The analyses were limited to patients with NMOSD and
MOGAD who were laboratory positive or highly suspected for
SARS-CoV-2 infection and reported by a health care professional in North America. Cohort characteristics were summarized using mean (SD) for continuous variables, median
(interquartile range) for ordinal variables, and frequencies (%)
for categorical variables.1 Comparisons between groups were
made using χ 2 tests, Fisher exact tests, and Student t-tests, as
appropriate, and reported descriptive statistics and p values.1
Similar statistical comparisons were performed between patients
with NMOSD and MS who died. Univariate logistic regression
models were constructed to examine the eﬀects of risk factors
and COVID-19 clinical severity outcome dichotomized as those
who were not hospitalized vs those hospitalized alone, admitted
to the ICU and/or ventilated or death.1 The strength of associations was reported using OR and 95% CI. Statistical analyses
were conducted using SAS V9.4 (SAS Institute Inc., Cary, NC).1

Results
Demographic and Clinical Characteristics of
Patients With NMOSD
As of June 7, 2021, there were 77 patients with NMOSD reported
in the COViMS Registry. Most patients were female (81.6%) and
in the United States at the time of COVID-19 (97.2%), with a
mean age (SD) of 48.1 (14.1) years (Table 1). Race and ethnicity
of patients were diverse with 38.2% Black, 25.0% non-Hispanic
White, 17.1% Hispanic or Latino, and 19.7% other racial groups.
The average NMOSD disease duration was 9.1 (7) years, and
67.2% were aquaporin-4 IgG seropositive. Although the majority
of patients with NMOSD were fully ambulatory (75.7%), some
required assistance with ambulation (14.9%), and 9.4% were
nonambulatory. At the time of COVID-19 diagnosis, most patients with NMOSD were on rituximab (62.2%), and 9.5% were
not on a DMT. Sixty percent had a comorbidity, with hypertension (20.8%), diabetes (15.6%), and morbid obesity (14.3%)
being the most frequent comorbidities reported. Only 4 (5.6%)
patients with NMOSD were current cigarette smokers.
Almost all (89.6%) patients with NMOSD were laboratory
positive for SARS-CoV-2. Fever (57.1%) and dry cough
(40.3%) were commonly reported symptoms of COVID-19,
whereas 2.6% of patients with NMOSD reported being
asymptomatic. Seven patients reported having neurologic
symptoms from COVID-19, with motor dysfunction occurring
in 3 of the 7 and cognitive and sensory dysfunction each in 2 of
Neurology.org/NN

the 7 patients. COVID-19 symptoms lasted 0–6 days in 13.3%
of patients with NMOSD, 7–13 days for 22.2%, 14–20 days for
20.0%, and 21 days or longer in 44.4% of patients. Of the 77
patients with NMOSD, 15.6% had pneumonia.
COVID-19 Outcomes in Patients With NMOSD
Most patients with NMOSD were not hospitalized (64.9% [95%
CI: 53.2%–75.5%]), whereas 15.6% (95% CI: 8.3%–25.6%)
were hospitalized only, and 9.1% (95% CI: 3.7%–17.8%) were
admitted to the ICU and/or ventilated. Over 10% (10.4%; 95%
CI: 4.6%–19.5%) died. No demographic characteristics were
statistically signiﬁcantly diﬀerent between those not hospitalized
and those hospitalized, admitted to the ICU, ventilated, or died
of COVID-19. Having a medical comorbidity was the only statistically signiﬁcant diﬀerence observed; those with a comorbidity were 6-fold more likely to have a poor clinical COVID-19
outcome compared with those with no comorbidity (OR = 6.0,
95% CI: 1.79–19.98).
A description of the demographic and clinical characteristics of
those 8 patients with NMOSD who died of COVID-19 is
reported in Table 2. All deceased patients with NMOSD had at
least 1 medical comorbidity. Five of the 8 (62.5%) fatal NMOSD
cases were aquaporin-4 IgG positive, and 4 (50%) were Black or
African American. Six (75.0%) of the 8 patients with NMOSD
who died of COVID-19 were on rituximab, but the proportion
of deaths among those taking rituximab was not statistically
diﬀerent than the proportion among those not on rituximab (6/
46 = 13.0% compared with 2/31 = 6.5%, p = 0.46). No significant diﬀerences were found among those taking rituximab vs
those not on rituximab among patients with NMOSD who were
hospitalized or worse (6/18 = 33.3% taking rituximab compared
with 2/9 = 29.0% not taking rituximab, p = 0.68).
Demographic and Clinical Characteristics of
Patients With MOGAD
Twenty patients with MOGAD with COVID-19 were reported
in the COViMS Registry. Most patients were female (70.0%)
with a mean (SD) age of 40.6 (18.7) years. One half identiﬁed
as non-Hispanic White. The average disease duration was 5.4
(5.0) years, and most patients with MOGAD were fully ambulatory (84.2%). Almost half of the patients with MOGAD
were on rituximab at the time of their COVID-19 diagnosis.
Forty-seven percent had a comorbidity, with hypertension
(25.0%), diabetes (15.0%), and morbid obesity (15.0%) being
the most common. Most patients were laboratory positive
(95.0%) for SARS-CoV-2. The most common symptoms from
COVID-19 reported in these patients with MOGAD were fever (60.0%), fatigue (55.0%), dry cough (45.0%), and shortness
of breath (4.0.%). The symptom duration was 0–14 days in
25.0% of patients with MOGAD, 14–20 days in 35.0%, 21 days
or longer in 10.0%, and unknown in 30.0%. Pneumonia was
reported in 4 (20.0%) patients.
COVID-19 Outcomes in Patients With MOGAD
Of the patients with MOGAD, 75.0% (95% CI: 50.9%–91.3%)
were not hospitalized, 10.0% (95% CI: 1.2%–31.7%) were
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Table 1 COViMS NMOSD Overall and by Clinical Outcome

Factor

Total (N = 77)

Not hospitalized
(n = 50)

Hospitalized,
ICU admission/
ventilation/death
(n = 27)

Female

62 (81.6)

43 (86.0)

19 (73.1)

0.17b

Age

48.1 (14.1)

46.9 (14.1)

50.3 (14.2)

0.33e

p Value

0.13b

Race
Non-Hispanic White

19 (25.0)

11 (22.4)

8 (29.6)

Black or African American

29 (38.2)

18 (36.7)

11 (40.7)

Hispanic or Latino

13 (17.1)

12 (24.5)

1 (3.7)

Other/unknown

15 (19.7)

8 (16.3)

7 (25.9)

9.1 (7.0)

8.6 (6.5)

10.2 (7.9)

c

Disease duration

0.47b

NMOSD type
NMO-IgG/aquaporin-4 antibody (+)

43 (55.8)

28 (56.0)

15 (55.6)

NMO-IgG/aquaporin-4 antibody (−)

15 (19.5)

8 (16.0)

7 (25.9)

Unknown

19 (24.7)

14 (28.0)

5 (18.5)
0.21d

Ambulatory status
Fully ambulatory

56 (75.7)

40 (81.6)

16 (64.0)

Walk with assistance

11 (14.9)

6 (12.2)

5 (20.0)

Nonambulatory

7 (9.5)

3 (6.1)

4 (16.0)
0.67d

Glucocorticoid during the last 2 months?
No

56 (72.7)

36 (72.0)

20 (74.1)

Yes

6 (7.8)

5 (10.0)

1 (3.7)

15 (19.5)

9 (18.0)

6 (22.2)

Unknown
DMT at the time of COVID-19

c

0.63d

Azathioprine

5 (6.8)

4 (8.5)

1 (3.7)

Eculizumab

5 (6.8)

4 (8.5)

1 (3.7)

Mycophenolate

5 (6.8)

4 (8.5)

1 (3.7)

Ocrelizumab

1 (1.4)

0 (0.0)

1 (3.7)

Rituximab

46 (62.2)

28 (59.6)

18 (66.7)

Other

5 (6.8)

2 (4.3)

3 (11.1)

7 (9.5)

5 (10.6)

2 (7.4)

None
Length of time on current DMT

c

0.49b
0.32b

<6 months
6 or more months

9 (13.8)

7 (17.1)

2 (8.3)

Have comorbidities?

56 (86.2)

34 (82.9)

22 (91.7)
0.004b

No
Yes

0.37a

29 (38.7)

25 (52.1)

4 (14.8)

Cancer

5 (6.5)

2 (4.0)

3 (11.1)

0.34d

Cardiovascular disease

6 (7.8)

4 (8.0)

2 (7.4)

0.99d

Cerebrovascular disease

1 (1.3)

1 (2.0)

0 (0.0)

0.99d
Continued

4
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Table 1 COViMS NMOSD Overall and by Clinical Outcome (continued)

Factor

Total (N = 77)

Not hospitalized
(n = 50)

Hospitalized,
ICU admission/
ventilation/death
(n = 27)

Chronic kidney disease

2 (2.6)

0 (0.0)

2 (7.4)

Chronic liver disease

0 (0.0)

0 (0.0)

0 (0.0)

Chronic lung disease

7 (9.1)

3 (6.0)

4 (14.8)

0.23d

Chronic neurologic disease

4 (5.2)

1 (2.0)

3 (11.1)

0.12d

Diabetes

12 (15.6)

7 (14.0)

5 (18.5)

0.60b

Hypertension

16 (20.8)

9 (18.0)

7 (25.9)

0.41b

Immunodeficiency disease

2 (2.6)

1 (2.0)

1 (3.7)

0.99d

Morbid obesity

11 (14.3)

4 (8.0)

7 (25.9)

0.032b

Other

12 (15.6)

8 (16.0)

4 (14.8)

0.89b

p Value
0.12d

0.027b

Comorbid conditions count
0

32 (41.6)

27 (54.0)

5 (18.5)

1

24 (31.2)

12 (24.0)

12 (44.4)

2

10 (13.0)

5 (10.0)

5 (18.5)

≥3

11 (14.3)

6 (12.0)

5 (18.5)
0.028b

Type of COVID-19 diagnosis
Laboratory positive

69 (89.6)

42 (84.0)

27 (100.0)

Suspected COVID-19, not confirmed

8 (10.4)

8 (16.0)

0 (0.0)

Abbreviations: COVID-19 = coronavirus disease 2019; COViMS = COVID-19 Infections in MS and Related Diseases; DMT = disease-modifying therapy; ICU =
intensive care unit; NMOSD = neuromyelitis optica spectrum disorders.
Values presented as mean ± SD, median (P25, P75) or N (column %).
a
Pearson χ2 test.
b
ANOVA.
c
Data not available for all patients. Missing values: sex = 1, age = 1, disease duration = 5, DMT at the time of COVID-19 = 2, and length of time on current DMT =
10.
d
Fisher exact test.
e
Kruskal-Wallis test.

hospitalized, and 15.0% (95% CI: 3.2%–37.9%) were admitted
to the ICU and/or ventilated. No deaths were recorded as of
June 7, 2021. A full listing of individual MOGAD patient clinical
characteristics, COVID-19 clinical outcome, and COVID-19
treatments is provided in Table 3. No demographic characteristic or clinical COVD-19 outcome was statistically diﬀerent
between those not hospitalized and those hospitalized, admitted
to the ICU, or ventilated (data not shown and available on
request). Notably, these comparisons were limited due to the
small number of patients with MOGAD who were reported.
Differences in COVID-19 Deaths Among
Patients With NMOSD and MS
Seventy-four patients with MS and 8 patients with NMOSD
died during the study time period. There were a few diﬀerences
in demographic and clinical characteristics between these groups
worth noting (Table 4). Speciﬁcally, the NMOSD cohort who
died were younger (50 ± 19.2 vs 62.1 ± 12.3, p = 0.016), had
shorter disease duration (9.3 ± 7.4 vs 20.6 ± 12.1, p = 0.012), and
Neurology.org/NN

a greater percentage of patients were on rituximab compared
with the patients with MS who died (75% vs 5.4%, p < 0.001).

Discussion
The COViMS Registry has provided a platform for collecting
clinician-reported data on patients with MS and related disorders
who developed COVID-19. These Registry data provide clinicians with useful information about how SARS-CoV-2 infection
aﬀects patients with NMOSD and MOGAD and indicate those
who might be at greatest risk for more severe COVID-19 outcomes. NMOSD and MOGAD are uncommon, and this study
represents the largest cohort of patients with NMOSD and
MOGAD with COVID-19 reported to date. A French study of
15 total patients with NMOSD and MOGAD (5 seropositive
NMOSD, 5 seronegative NMOSD, and 5 with MOGAD) with
COVID-19 reported an association of older age and more disability with hospitalization, but no deaths.3
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Table 2 Demographic and Clinical Characteristics of Deceased Patients With NMOSD

Sex

Age Race

US state at the
time of COVID-19
onset

Disease
duration
(y)

NMOSD
antibody
serostatus

Ambulatory
status

DMT at the
time of
COVID-19

Comorbidities

Pneumonia

Length of
hospital
stay
4–6 d

COVID-19 treatments

Female 73

NonHispanic
White

Colorado

2

Positive

Walk with
assistance

None

Cancer, cardiovascular
disease, and chronic lung
disease

Yes

Female 30

Black or
African
American

Florida

2

Negative

Fully
ambulatory

Rituximab

Diabetes and morbid
obesity

Yes–bilateral 19–21 d

Antiviral and other antibiotic, convalescent
plasma, tocilizumab, and oxygen therapy

Female 55

Other/
unknown

Unknown

9

Positive

Walk with
assistance

Rituximab

Hypertension

Unknown

30+ d

Unknown

Female 39

Black or
African
American

Washington

10

Positive

Nonambulatory Other

Chronic kidney disease
and morbid obesity

Unknown

4–6 d

Unknown

Female 26

Black or
African
American

California

5

Positive

Fully
ambulatory

Diabetes and morbid
obesity

Yes

Unknown

Unknown

Male

80

NonHispanic
White

Missouri

25

Negative

Nonambulatory Rituximab

Hypertension

No

7–9 d

Unknown

Female 46

NonHispanic
White

Vermont

8

Negative

Fully
ambulatory

Rituximab

Diabetes, hypertension,
and morbid obesity

Yes–bilateral 30+ d

Antiviral, systemic glucocorticoids, other antiinflammatory agents, oxygen therapy, IVIG, and
convalescent plasma

Female 52

Black or
African
American

Kentucky

13

Positive

Fully
ambulatory

Rituximab

Chronic lung disease and
hypertension

Yes–bilateral 30+ d

Systemic glucocorticoids, azithromycin, other
antibiotics, oxygen therapy, and IVIG

Rituximab

Hydroxychloroquine, azithromycin, and oxygen
therapy

Abbreviations: COVID-19 = coronavirus disease 2019; DMT = disease-modifying therapy; IVIG = intravenous immunoglobulin; NMOSD = neuromyelitis optica spectrum disorders.
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Table 3 Demographic and Clinical Characteristics of Patients With MOGAD Reported in the COViMS Registry
Sex

Age Race

US state at the time of Disease
COVID-19 onset
duration

Ambulatory
status

DMT at the time
of COVID-19
Comorbidities

COVID-19 clinical
severity outcome

Pneumonia

Length of
hospital stay COVID-19 treatments

Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 5 | September 2021

Female 67

Black or
African
American

Unknown

15

Fully
ambulatory

Mycophenolate

Cancer, chronic lung
disease, and diabetes

Admitted to the ICU
and/or ventilated

No

13–15 d

Hydroxychloroquine and
systemic glucocorticoids

Male

54

Non-Hispanic
White

Kansas

3

Fully
ambulatory

Rituximab

Hypertension

Admitted to the ICU
and/or ventilated

Yes–bilateral

7–9 d

Chloroquine, azithromycin, and
oxygen therapy

Female 19

Non-Hispanic
White

California

3

Fully
ambulatory

Mycophenolate

No

Hospitalization only

Yes–bilateral

4–6 d

Hydroxychloroquine,
azithromycin, and other
antibiotics

Female 26

Non-Hispanic
White

Unknown–United
States

2

Fully
ambulatory

Rituximab

Obesity

Not hospitalized

No

—

None

Female 58

Hispanic or
Latino

Missouri

7

Fully
ambulatory

None

No

Not hospitalized

No

—

Systemic glucocorticoids

Female 32

Other/
unknown

California

3

Fully
ambulatory

Rituximab

Morbid obesity

Not hospitalized

No

—

Azithromycin

Female 43

Non-Hispanic
White

Kentucky

2

Walk with
assistance

Azathioprine

Diabetes, hypertension,
and morbid obesity

Not hospitalized

Yes–unilateral —

Azithromycin

Female 20

Hispanic or
Latino

Unknown–United
States

8

Fully
ambulatory

Fingolimod

Migraines

Not hospitalized

No

—

None

Female 62

Other/
unknown

California

2

Fully
ambulatory

Rituximab

None

Not hospitalized

No

—

Tylenol

Female 26

Non-Hispanic
White

Rhode Island

2

Fully
ambulatory

Rituximab

No

Not hospitalized

No

—

Unknown

Female 64

Other/
unknown

Unknown–United
States

0

Walk with
assistance

Rituximab

Diabetes, hypertension,
hyperlipidemia, and
obstructive sleep apnea

Not hospitalized

No

—

None

Female 25

Non-Hispanic
White

Nebraska

15

Fully
ambulatory

IVIG

None

Not hospitalized

No

—

Bamlanivimab

Male

69

Other/
unknown

Canada

4

Fully
ambulatory

None

Cancer and hypertension Not hospitalized

No

—

None

Male

58

Non-Hispanic
White

Ohio

2

Fully
ambulatory

Rituximab

Hypertension and
morbid obesity

Admitted to the ICU
and/or ventilated

Yes–bilateral

1–3 d

Unknown monoclonal antibody
infusion

Female 27

Non-Hispanic
White

Canada

4

Fully
ambulatory

Azathioprine

None

Not hospitalized

No

—

None

Male

Other/
unknown

Canada

Unknown

Unknown

Unknown

None

Not hospitalized

No

—

Unknown

27

Continued
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Abbreviations: COVID-19 = coronavirus disease 2019; COViMS = COVID-19 Infections in MS and Related Diseases; DMT = disease-modifying therapy; ICU = intensive care unit; IVIG = intravenous immunoglobulin;
NMOSD = neuromyelitis optica spectrum disorders; MOGAD = myelin oligodendrocyte glycoprotein antibody disease.

None
—
No
Female 20

Other/
unknown

Fully
ambulatory

None
11
Canada

None

Not hospitalized

None
—
No
Non-Hispanic
White
Male

60

Fully
ambulatory

None
3
Missouri

None

Not hospitalized

None
—
No
Non-Hispanic
White
Male

17

Fully
ambulatory

None
2
Unknown–United
States

Unknown

Not hospitalized

Unknown
Unknown
No
Nonambulatory Rituximab
15
Female 38

Hispanic or
Latino

New Jersey

None

Hospitalization only

Length of
hospital stay COVID-19 treatments
Pneumonia
COVID-19 clinical
severity outcome
DMT at the time
of COVID-19
Comorbidities
Ambulatory
status
US state at the time of Disease
COVID-19 onset
duration
Age Race
Sex

Table 3 Demographic and Clinical Characteristics of Patients With MOGAD Reported in the COViMS Registry (continued)
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Approximately two-thirds of patients with NMOSD in the
COViMS Registry did not require hospitalization; however,
10.4% of the entire cohort died (8/77). This mortality rate is
notable for being 4 times the rate than what was seen with
patients with MS in COViMS and almost 6 times greater than
that reported for the general population in the United
States.1,4 However, a 95% CI ranging from 4.6% to 19.5%
leaves some uncertainty as to the level of excess risk. A large
percentage of the NMOSD cohort were Black and on rituximab, both of which are known risk factors for severe COVID19 in other populations.1,2,5 The sole factor that identiﬁed
statistically poorer COVID-19 outcome in NMOSD was the
presence of a medical comorbidity, which resulted in 6-fold
greater odds of worse COVID-19 outcomes. The most
common medical comorbidities in this cohort were hypertension, diabetes, and morbid obesity, which have also been
observed to increase risks of poor outcome from COVID-19
in the general population.
In the MS population within the COViMS Registry and in
other registries/surveys, common risk factors for severe
COVID-19 outcomes included older age, male sex, Black
race, higher disability level, recent corticosteroid use, and
use of B cell–depleting therapies.1,2,5 No demographic or
DMT diﬀerences were observed in relation to NMOSD
outcomes, although our statistical power to identify diﬀerences was limited. Overall, almost 60% of patients with
NMOSD with COVID-19 in COViMS were treated with
B cell–depleting therapies (46/77), and the proportion of
NMOSD taking rituximab with fatal outcomes was nominally higher compared with those not taking rituximab
(13.0% vs 6.5%). In addition, a large proportion of
NMOSD were of Black race (29/77), and 4 of the 8 deaths
were in NMOSD of Black race. Hence, with a larger sample
size, rituximab and Black race could prove to be additional
risk factors for severe COVID-19 in NMOSD. In fact, to
achieve an 80% power to detect a diﬀerence in more
severe outcomes between these groups, it would require
over 200 patients per group. Thus, precautions to prevent
exposure to SARS-CoV-2 in patients with NMOSD are
recommended.6,7 Moreover, COVID-19 vaccination has
been strongly encouraged by infectious disease experts and
the Centers for Disease Control and Prevention, especially
for those who are at high risk for more severe COVID-19
disease, and thus COVID-19 vaccination in NMOSD may
be particularly important.6,7
None of the 20 patients with MOGAD with COVID-19 in the
COViMS Registry died, and only 5 required hospitalization.
Patients with MOGAD in this cohort had similar comorbidities as those with NMOSD, and almost half were taking
rituximab. Not identifying speciﬁc risks factors of poorer
outcomes with COVID-19 in MOGAD is likely due to the
small size of the cohort.
Altering B cell–depleting therapy dosage and/or frequency of
administration during the COVID-19 pandemic has been
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Table 4 Differences in COVID-19 Deaths Among Patients With MS and NMO in COViMS
Factor

Total (N = 82)

MS (n = 74)

NMO (n = 8)

0.21b

Sex
Male

35 (42.7)

34 (45.9)

1 (12.5)

Female

46 (56.1)

39 (52.7)

7 (87.5)

Nonbinary

1 (1.2)

1 (1.4)

0 (0.0)

60.9 (13.5)

62.1 (12.3)

50.1 (19.2)

Age

Non-Hispanic White

54 (65.9)

51 (68. 9)

3 (37.5)

Black or African American

20 (24.4)

16 (21.6)

4 (50.0)

Hispanic or Latino

2 (2.4)

2 (2.7)

0 (0.0)

Other/unknown

6 (7.3)

5 (6.8)

1 (12.5)

Country at the time of COVID-19 onsetc

0.99b

United States

77 (97.5)

70 (97.2)

7 (100.0)

Canada

1 (1.3)

1 (1.4)

0 (0.0)

Other

1 (1.3)

1 (1.4)

0 (0.0)

19.3 (12.2)

20.6 (12.1)

9.3 (7.4)

Ambulatory statusc

0.012e
0.075b

Fully ambulatory

15 (20.5)

11 (16.9)

4 (50.0)

Walk with assistance

20 (27.4)

18 (27.7)

2 (25.0)

Nonambulatory

38 (52.1)

36 (55.4)

2 (25.0)
0.45a

Glucocorticoid during the last 2 months?
No

54 (76.1)

48 (75.0)

6 (85.7)

Yes

6 (8.5)

5 (7.8)

1 (14.3)

Unknown

11 (15.5)

11 (17.2)

0 (0.0)

DMT at the time of COVID-19c

0.002b

Alemtuzumab

1 (1.3)

1 (1.5)

0 (0.0)

Dimethyl fumarate

4 (5.3)

4 (5.9)

0 (0.0)

Glatiramer acetate

2 (2.6)

2 (2.9)

0 (0.0)

Interferon-beta

1 (1.3)

1 (1.5)

0 (0.0)

Mycophenolate

1 (1.3)

1 (1.5)

0 (0.0)

Natalizumab

3 (3.9)

3 (4.4)

0 (0.0)

Ocrelizumab

19 (25.0)

19 (27.9)

0 (0.0)

Rituximab

10 (13.2)

4 (5.9)

6 (75.0)

Siponimod

2 (2.6)

2 (2.9)

0 (0.0)

Teriflunomide

5 (6.6)

5 (7.4)

0 (0.0)

Other

2 (2.6)

1 (1.5)

1 (12.5)

None

26 (34.2)

25 (36.8)

1 (12.5)
<0.001a

Rituximab use
No

0.016e
0.18b

Race

Disease durationc

p Value

72 (87.8)

70 (94.6)

2 (25.0)
Continued
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Table 4 Differences in COVID-19 Deaths Among Patients With MS and NMO in COViMS (continued)
Factor
Yes
Length of time on current DMT

Total (N = 82)

MS (n = 74)

NMO (n = 8)

10 (12.2)

4 (5.4)

6 (75.0)

c

p Value

0.99b

<6 months

1 (2.1)

1 (2.4)

0 (0.0)

6 or more months

46 (97.9)

40 (97.6)

6 (100.0)
0.99b

Have comorbidities?
No

6 (7.3)

6 (8.1)

0 (0.0)

Yes

72 (87.8)

64 (86.5)

8 (100.0)

Unknown

4 (4.9)

4 (5.4)

0 (0.0)

Cancer

7 (8.5)

6 (8.1)

1 (12.5)

0.67a

Cardiovascular disease

22 (26.8)

21 (28.4)

1 (12.5)

0.34a

Cerebrovascular disease

1 (1.2)

1 (1.4)

0 (0.0)

0.99b

Chronic kidney disease

7 (8.5)

6 (8.1)

1 (12.5)

0.67a

Chronic liver disease

3 (3.7)

3 (4.1)

0 (0.0)

0.99b

Chronic lung disease

7 (8.5)

5 (6.8)

2 (25.0)

0.079a

Chronic neurologic disease

9 (11.0)

8 (10.8)

1 (12.5)

0.88a

Diabetes

17 (20.7)

14 (18.9)

3 (37.5)

0.22a

Hypertension

43 (52.4)

39 (52.7)

4 (50.0)

0.99b

Immunodeficiency disease

4 (4.9)

4 (5.4)

0 (0.0)

0.99b

Morbid obesity

19 (23.2)

15 (20.3)

4 (50.0)

0.058a

Other

26 (31.7)

25 (33.8)

1 (12.5)

0.22a

Pneumonia

27 (32.9)

22 (29.7)

5 (62.5)

0.061a
0.18a

Emergency department visited?
Yes

59 (72.0)

51 (68.9)

8 (100.0)

No

8 (9.8)

8 (10.8)

0 (0.0)

Unknown

15 (18.3)

15 (20.3)

0 (0.0)
0.30b

Hospitalized?
Yes

70 (85.4)

63 (85.1)

7 (87.5)

No

9 (11.0)

9 (12.2)

0 (0.0)

Unknown

3 (3.7)

2 (2.7)

1 (12.5)
0.27b

Admitted to the ICU?
Yes

51 (62.2)

45 (60.8)

6 (75.0)

No

18 (22.0)

18 (24.3)

0 (0.0)

Unknown

13 (15.9)

11 (14.9)

2 (25.0)
0.21b

Ventilation?
Yes

41 (50.0)

38 (51.4)

3 (37.5)

No

22 (26.8)

21 (28.4)

1 (12.5)

Unknown

19 (23.2)

15 (20.3)

4 (50.0)
Continued
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Table 4 Differences in COVID-19 Deaths Among Patients With MS and NMO in COViMS (continued)
Factor

Total (N = 82)

MS (n = 74)

NMO (n = 8)

p Value
0.99b

Type of COVID-19 diagnosis
Laboratory positive

77 (93.9)

69 (93.2)

8 (100.0)

Suspected COVID-19, not confirmed

5 (6.1)

5 (6.8)

0 (0.0)

Abbreviations: COVID-19 = coronavirus disease 2019; COViMS = COVID-19 Infections in MS and Related Diseases; DMT = disease-modifying therapy.
Values presented as mean ± SD, median (P25, P75), median (min, max) or N (column %).
Fisher exact test.
b
ANOVA.
c
Data not available for all patients. Missing values: country at the time of COVID-19 onset, disease duration = 10, ambulatory status = 9, glucocorticoid during
the last 2 months, DMT at the time of COVID-19 = 6, and length of time on current DMT = 35.
d
Pearson χ2 test.
e
Kruskal-Wallis test.
a

considered in patients with MS because of the mounting
evidence that these agents increase the risk of infections,
including COVID-19, in MS.1-3,8 Some studies have suggested that patients with MS can achieve similar suppression of new inﬂammatory disease activity with lower doses
and/or extended intervals between doses of rituximab or
ocrelizumab.9-12 It is unclear whether these treatment approaches would be applicable to NMOSD but may be of
interest especially because the main diﬀerence in clinical
characteristics between patients with NMOSD and MS in
COViMS was the use of rituximab. Of interest, 2 small case
series in NMOSD have shown that it might be possible to
prevent future clinical NMOSD relapses along with reducing the risk of infections by using lower doses of rituximab and/or with a decrease in frequency of rituximab
infusions.13,14 Moreover, it may be reasonable in some patients (e.g., NMOSD with medical comorbidities and
NMOSD with hypogammaglobulinemia) to consider tailoring their treatment regimen in hopes to minimize infectious risks.15
Last, in the COViMS Registry, 7 patients with NMOSD who
were alive reported having neurologic symptoms in relation to
COVID-19 including motor dysfunction (42.9%) and cognitive and sensory dysfunction (28.6%). Because of the nature of
data collection in the COViMS Registry, it is unclear whether
these symptoms were due to a provoked relapse, pseudorelapse, or neurologic complications from COVID-19 as has
been seen in other patient populations.16 Neurologic symptoms were not reported in the patients with MOGAD in this
registry.
Limitations of this study include the small sample size
relative to more common diseases (e.g., MS). This study is
not population-based, as has been a limitation in many
COVID-19 studies. Reporting biases may be present;
reporting is voluntary, and more severe outcomes might
have been disproportionately captured. Additional risk
factors for more severe COVID-19 outcomes might be
uncovered with a larger sample size, with studies from
areas of the world where NMOSD and MOGAD are
Neurology.org/NN

particularly prevalent, or when combining data from different registries.

Conclusions
Among the reported patients with NMOSD, a high mortality rate was observed, and the presence of comorbid
conditions was associated with worse COVID-19 outcome.
There were no deaths reported in the patients with
MOGAD, an observation that was limited due to small
sample size.
Overall, these results suggest that it is of utmost importance
for people with NMOSD to be especially vigilant and avoid
exposure and adopt measures to minimize the risk of infection by SARS-CoV-2. Data will continue to be collected
via the COViMS Registry to help enhance our understanding of how infection by SARS-CoV-2 aﬀects both
NMOSD and MOGAD.
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